Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C20T5
- Development stage
- Phase 3
- Lead developer
- Murdoch Children's Research Institute
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**C20T5** is a Cannatrek medicinal cannabis oral oil product marketed as a CBD-predominant formulation containing cannabidiol and delta-9-tetrahydrocannabinol. The product designation denotes a formulation containing approximately 20 mg/mL cannabidiol and 5 mg/mL delta-9-tetrahydrocannabinol. It was evaluated by Murdoch Childrens Research Institute in the randomized pilot trial NCT05615389 in children and young people receiving palliative care for non-oncological conditions. Its therapeutic activity is mediated principally through cannabinoid receptor signaling, with delta-9-tetrahydrocannabinol acting as a partial agonist at cannabinoid receptors 1 and 2, while cannabidiol has broader modulatory pharmacology across the endocannabinoid system and other signaling pathways.
- Brand names
- C20T5 Ruby CBD OilC-20T5 Ruby CBD OilC 20T5 Ruby CBD OilCannatrek C20T5 Ruby
- Other names
- C20T5C-20T5C 20T5
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)CNR2 (Cannabinoid receptor type 2)FAAHGABRR (GABA-A receptor subunit rho)GPR55 (G protein-coupled receptor 55)Glycine receptorPPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on C20T5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C20T5.